Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results

NCT01968486 is registered in ClinicalTrials.gov with University of Campania Luigi Vanvitelli as lead sponsor.

NCT NCT01968486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01968486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results
Lead sponsor
University of Campania Luigi Vanvitelli
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
July 31, 2013
Enrollment
60 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myopia, degenerative